種由来 |
Human
|
適用 |
Immuno Fluorescence Flow Cytometry Functional Assay
|
免疫動物 |
Mouse
|
抗体クラス |
IgG1
|
クローン |
3E7
|
形状 |
溶液
|
参考文献 |
1. Kennedy, A et al; An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition and killing of CD20 cells by rituximab. Blood 2003, 101:3 2. Kennedy, A et al; Rituximab infusion promotes rapid complement depletion and acute CD20 loss in Chronic Lymphocytic Leukemia. Journal of Immunology 2004, 172:5 3. Pawluczkowycz, A et al; Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: Potential implications for the pathogenesis of anemia in malaria. Journal of Immunology 2007, 178:8 4. Risitano, AM; Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 2012, 217:11 5. Lindorfer, M et al; A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115:11 6. DiLillo, D et al; Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Molecular Immunology 2006, 43:7 7. PaixA£o-Cavalvante, D et al; A humanized antibody that regulates the alternative pathway convertase: Potential for therapy of renal disease associated with nephritic factors. Journal of Immunology 2014, 192:10 8. Beum, P et al; Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. Journal of immunology 2008, 181:1
|
|
メーカー |
品番 |
包装 |
HCB
|
HM2286-100UG
|
100 UG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
2週間程度
|
保存温度 |
4℃
|
|